TY - JOUR
T1 - Targeting aggrephagy for the treatment of Alzheimer’s disease
AU - Malampati, Sandeep
AU - Song, Ju Xian
AU - Chun-Kit Tong, Benjamin
AU - Nalluri, Anusha
AU - Yang, Chuan-Bin
AU - Wang, Ziying
AU - Gopalkrishnashetty Sreenivasmurthy, Sravan
AU - Zhu, Zhou
AU - Liu, Jia
AU - Su, Chengfu
AU - Krishnamoorthi, Senthilkumar
AU - Iyaswamy, Ashok
AU - Cheung, King-Ho
AU - Lu, Jia-Hong
AU - Li, Min
N1 - This work is supported by the National Natural Science Foundation of China (NSFC/81773926, NSFC/81703487), Hong Kong General Research Fund (HKBU121006/18, HKBU121014/17), The Hong Kong Health and Medical Fund (HMRF15163481, HMRF14150811), and Hong Kong Baptist University Research Fund (HKBU/RC-IRCs/17-18/03, HKBU/RC-IRMS/15-16/04, FRGII/17-18/021, and FRGII/16-17/018) to Min Li.
Publisher copyright:
© The Author(s) 2020
PY - 2020/2
Y1 - 2020/2
N2 - Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in older individuals with specific neuropsychiatric symptoms. It is a proteinopathy, pathologically characterized by the presence of misfolded protein (Aβ and Tau) aggregates in the brain, causing progressive dementia. Increasing studies have provided evidence that the defect in protein-degrading systems, especially the autophagy-lysosome pathway (ALP), plays an important role in the pathogenesis of AD. Recent studies have demonstrated that AD-associated protein aggregates can be selectively recognized by some receptors and then be degraded by ALP, a process termed aggrephagy. In this study, we reviewed the role of aggrephagy in AD development and discussed the strategy of promoting aggrephagy using small molecules for the treatment of AD.
AB - Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in older individuals with specific neuropsychiatric symptoms. It is a proteinopathy, pathologically characterized by the presence of misfolded protein (Aβ and Tau) aggregates in the brain, causing progressive dementia. Increasing studies have provided evidence that the defect in protein-degrading systems, especially the autophagy-lysosome pathway (ALP), plays an important role in the pathogenesis of AD. Recent studies have demonstrated that AD-associated protein aggregates can be selectively recognized by some receptors and then be degraded by ALP, a process termed aggrephagy. In this study, we reviewed the role of aggrephagy in AD development and discussed the strategy of promoting aggrephagy using small molecules for the treatment of AD.
KW - aggrephagy
KW - selective autophagy
KW - Alzheimer’s disease
KW - aggregates
UR - http://www.scopus.com/inward/record.url?scp=85089725259&partnerID=8YFLogxK
U2 - 10.3390/cells9020311
DO - 10.3390/cells9020311
M3 - Review article
C2 - 32012902
AN - SCOPUS:85089725259
SN - 2073-4409
VL - 9
JO - Cells
JF - Cells
IS - 2
M1 - 311
ER -